An observational study in Thalassemia, Sickle Cell Disease and Hemolytic Anemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This cross-sectional study aims to evaluate advanced reticulocyte parameters in patients with thalassemia and sickle cell disease compared with healthy controls.
Hemolytic anemia is characterized by premature destruction of red blood cells. Reticulocytes are immature red blood cells released from the bone marrow, and their assessment reflects erythropoietic activity.
Modern automated hematology analyzers provide advanced reticulocyte parameters including reticulocyte percentage, absolute reticulocyte count, reticulocytes with low, medium and high ribonucleic acid (RNA) content, immature reticulocyte fraction, mean reticulocyte volume, and reticulocyte hemoglobin content.
This observational study will measure these advanced reticulocyte parameters in adult patients with beta-thalassemia, patients with sickle cell disease, and healthy controls.
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
This study's planned enrollment of 90 is below the median of 106 across 70 observational studies indexed under Thalassemia.
Browse Thalassemia studies →Assiut University is the lead sponsor of 5,088 studies on the registry; 2,185 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with beta-thalassemia, patients with sickle cell disease, and healthy controls attending Assiut University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with beta-thalassemia.
Patients diagnosed with sickle cell disease.
Apparently healthy individuals without anemia or hemoglobinopathy.
Immature reticulocyte fraction
Mean immature reticulocyte fraction measured by automated hematology analyzer (percentage).
Time frame: Baseline
Absolute reticulocyte count
Mean absolute reticulocyte count measured by automated hematology analyzer (cells per microliter).
Time frame: Baseline
Reticulocyte percentage
Mean reticulocyte percentage measured by automated hematology analyzer.
Time frame: Baseline
Reticulocyte hemoglobin content
Mean reticulocyte hemoglobin content measured by automated hematology analyzer (picograms).
Time frame: Baseline
Mean reticulocyte volume
Mean reticulocyte volume measured by automated hematology analyzer (femtoliters).
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.